There are 2789 resources available
288P - Real-world outcomes and safety of pyrotinib in HER2-positive metastatic breast cancer (MBC) patients: A prospective cohort study
Presenter: Ting Luo
Session: ePoster Display
289P - A retrospective population-based observational study in metastatic HER2-positive breast cancer patients in Denmark previously treated with T-DM1
Presenter: Asbjørn Due
Session: ePoster Display
290P - Treatment with tyrosine kinase inhibitors (TKIs) based therapy in trastuzumab emtansine (T-DM1) resistant HER2-positive metastatic breast cancer: A real-world study
Presenter: Yijia Hua
Session: ePoster Display
291P - HER2-low metastatic breast cancer (MBC): Management and prognosis of a new breast cancer entity in a real-world setting
Presenter: Jean-Sebastien Frenel
Session: ePoster Display
293P - Exploring the interplay between tumor burden and liquid biopsy longitudinal evaluation in hormone receptor-positive, HER2-negative metastatic breast cancer (MBC)
Presenter: Roberta Mazzeo
Session: ePoster Display
294P - Cell-free DNA (cfDNA) workflow for the risk definition of dose-limiting and recurrent neutropenia in patients treated with first-line endocrine therapy (ET) and cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) for metastatic breast cancer (MBC)
Presenter: Lorenza Palmero
Session: ePoster Display
295P - Clinical characterization and outcome of a HER2-low metastatic breast cancer (mBC) cohort receiving first-line treatment (1L) with ET +/- CDK 4/6 inhibitor (CDKi)
Presenter: Lucia Bortot
Session: ePoster Display
296P - Recapitulation of organ-specific breast cancer metastasis using an engineered multi-tissue platform
Presenter: Alan Chramiec
Session: ePoster Display
297P - Transcriptomic modification induced by the first cycle of neoadjuvant chemotherapy impacts response to treatment in triple-negative breast cancer (TNBC)
Presenter: Isabelle Desmoulins
Session: ePoster Display